Simulations Plus, Inc. announced on June 20 that it acquired Immunetrics, Inc.
Simulations Plus agreed to pay the shareholders of Immunetrics cash consideration of $15.5 million. This includes a $1.8 million hold-back, plus two future earn-out payments in the aggregate amount of up to $8 million based on the revenue performance of Immunetrics through December 31, 2024.
Immunetrics has served major pharmaceutical companies with predictive-modeling solutions to support the design of clinical trials. Immunetrics’ technology includes a broad and continually expanding library of standardized disease progression models, as well as Thales, a comprehensive quantitative systems pharmacology model-development platform.
Lancaster, California-based Simulations Plus develops and sells drug discovery and development software for mechanistic modeling and simulation. In 2022, the company generated a revenue of $53.45 million.
The acquisition of Immunetrics leverages Simulations Plus’ existing infrastructure by expanding its therapeutic resources into largely underserved areas, including immunology and oncology.
According to data captured in the LevinPro HC database, this transaction represents the 14th clinical trials acquisition of 2023.
